Physician
Bruyninckx Medical LLC
Bruyninckx Medical LLC was paid $2.20M by Medicaid between Mar 2021 and Dec 2024, across 103 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 32% of everything it billed.
33Billing provider infoBRUYNINCKX MEDICAL LLC
RAYVILLE, LA 71269
RAYVILLE, LA 71269
33aNPI1700481660assigned 11/30/2020
33bProvider typePediatrics Physician
28Total paid$2.20M
24GClaims148,198
24DCodes billed103
24AFirst – last monthMar 2021 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Louisiana
Rank by total paid#54 of 230
Median peer was paid$429K
This provider vs. median5.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 24,982 | $338K | |
| 2022 | 38,184 | $618K | |
| 2023 | 48,215 | $744K | |
| 2024incomplete | 36,817 | $500K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 32% | 19,525 | 13,653 | $703K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 20% | 13,398 | 9,724 | $443K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 7.7% | 6,043 | 4,973 | $169K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 6.4% | 2,257 | 1,194 | $141K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.3% | 770 | 665 | $72K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.2% | 1,233 | 939 | $71K |
| 71046 | Radiologic examination, chest; 2 views | 3.1% | 4,788 | 3,763 | $69K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.9% | 8,278 | 4,381 | $63K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.8% | 1,071 | 746 | $40K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.7% | 1,057 | 613 | $38K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 1,413 | 1,219 | $29K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 2,347 | 2,015 | $28K |
91 more codes
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.2% | 504 | $27K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 4,852 | $26K |
| 74018 | 1.1% | 1,916 | $24K | |
| 87807 | <1% | 2,031 | $20K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,626 | $18K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 293 | $17K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,366 | $17K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,415 | $14K |
| 82607 | <1% | 1,161 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 150 | $10K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 567 | $9K |
| 82962 | <1% | 5,860 | $9K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 895 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,877 | $8K |
| 84480 | <1% | 1,626 | $8K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 177 | $8K |
| 72100 | <1% | 533 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 238 | $7K |
| 82670 | <1% | 304 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,456 | $6K |
| 84436 | <1% | 1,612 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 344 | $5K |
| 87634 | <1% | 88 | $5K | |
| 84144 | <1% | 287 | $5K | |
| 93000 | <1% | 527 | $4K | |
| 81002 | <1% | 2,393 | $4K | |
| 11056 | <1% | 298 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 115 | $3K |
| 90674 | <1% | 173 | $3K | |
| 99417 | Prolong home eval add 15m | <1% | 265 | $3K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 420 | $3K |
| 81025 | <1% | 568 | $3K | |
| 73562 | <1% | 233 | $3K | |
| 99406 | <1% | 873 | $3K | |
| 70220 | <1% | 183 | $2K | |
| 72040 | <1% | 146 | $2K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 25 | $2K |
| 90686 | <1% | 274 | $1K | |
| 84403 | <1% | 62 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 841 | $1K |
| 90682 | <1% | 28 | $1K | |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | <1% | 406 | $937.26 |
| 73030 | <1% | 86 | $728.53 | |
| 90474 | <1% | 97 | $721.27 | |
| 99381 | <1% | 20 | $693.46 | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 675 | $668.83 |
| 17000 | <1% | 29 | $607.72 | |
| 90661 | <1% | 200 | $589.74 | |
| 80305 | <1% | 114 | $572.22 | |
| 11200 | <1% | 22 | $433.44 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,987 | $398.87 |
| 90670 | <1% | 192 | $345.00 | |
| 73502 | <1% | 24 | $313.17 | |
| 86308 | <1% | 66 | $285.90 | |
| 69210 | <1% | 21 | $282.09 | |
| 90688 | <1% | 19 | $243.12 | |
| 74019 | <1% | 17 | $209.16 | |
| 90671 | <1% | 221 | $200.43 | |
| 3044F | <1% | 122 | $170.00 | |
| 82950 | <1% | 115 | $155.46 | |
| 73630 | <1% | 13 | $152.18 | |
| 90697 | <1% | 289 | $150.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,683 | $147.95 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,583 | $131.17 |
| 96161 | <1% | 122 | $113.96 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 293 | $82.50 |
| 99188 | <1% | 15 | $72.15 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,045 | $65.12 |
| 17003 | <1% | 24 | $50.85 | |
| 90461 | <1% | 201 | $41.25 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 488 | $39.09 |
| 99173 | <1% | 16 | $17.19 | |
| 96127 | <1% | 57 | $10.95 | |
| 81005 | <1% | 39 | $10.80 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 400 | $7.20 |
| 3074F | <1% | 202 | $0.09 | |
| 90633 | <1% | 63 | $0.09 | |
| 90651 | <1% | 20 | $0.04 | |
| 3079F | <1% | 108 | $0.04 | |
| 3078F | <1% | 173 | $0.04 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 48 | $0.03 |
| 3080F | <1% | 133 | $0.03 | |
| 3075F | <1% | 84 | $0.01 | |
| 3077F | <1% | 125 | $0.01 | |
| G0008 | Administration of influenza virus vaccine | 0% | 49 | $0.00 |
| 4000F | 0% | 18 | $0.00 | |
| 90694 | 0% | 30 | $0.00 | |
| 87631 | 0% | 356 | $0.00 | |
| 90681 | 0% | 32 | $0.00 | |
| 96367 | 0% | 74 | $0.00 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 200 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRUYNINCKX, KYLE (MD)